Background. Maintenance of central blood volume (CBV) is essential for hemodynamic stability during hemodialysis (HD), though preservation of CBV is poorly understood. Pneumatic compression devices (PCDs) during HD may help maintain CBV. Methods. We performed a randomized, crossover trial to determine the effect of PCDs on CBV during HD. Patients underwent two consecutive mid-week HD sessions, randomized to begin the first session either with or without PCDs [stratified by intradialytic hypotension (IDH)-prone status]. The primary outcome was change in CBV during HD. The secondary outcomes were change in other hemodynamic and volume status parameters. Results. Fifty-one patients (median age 65 years, 75% male, 22% IDH-prone) were randomized; forty-six completed the study. During HD, the median change in CBV for PCD and control sessions was −0.08 versus −0.05 L (P = 0.62). There was no difference in the change in cardiac output (CO) (−0.63 versus −0.49 L/min, P = 0.78) or systemic vascular resistance (SVR) (+1.30 versus +1.55 mmHg/L/min, P = 0.67) for PCDs versus control. Based on the bioimpedance measurements, patients were not volume overloaded pre-
A B S T R AC T
Background. Maintenance of central blood volume (CBV) is essential for hemodynamic stability during hemodialysis (HD), though preservation of CBV is poorly understood. Pneumatic compression devices (PCDs) during HD may help maintain CBV. Methods. We performed a randomized, crossover trial to determine the effect of PCDs on CBV during HD. Patients underwent two consecutive mid-week HD sessions, randomized to begin the first session either with or without PCDs [stratified by intradialytic hypotension (IDH)-prone status]. The primary outcome was change in CBV during HD. The secondary outcomes were change in other hemodynamic and volume status parameters. Results. Fifty-one patients (median age 65 years, 75% male, 22% IDH-prone) were randomized; forty-six completed the study. During HD, the median change in CBV for PCD and control sessions was −0.08 versus −0.05 L (P = 0.62). There was no difference in the change in cardiac output (CO) (−0.63 versus −0.49 L/min, P = 0.78) or systemic vascular resistance (SVR) (+1.30 versus +1.55 mmHg/L/min, P = 0.67) for PCDs versus control. Based on the bioimpedance measurements, patients were not volume overloaded predialysis. There was a greater reduction in total body water (TBW) (−2.6 versus −2.3 L, P = 0.05) and intracellular fluid (ICF) volume (−1.3 versus −1.1 L, P = 0.03), and no difference in change in the extracellular fluid (ECF) volume (1.3 versus 1.2 L, P = 0.09) with PCDs versus control. Similar results were observed in IDH-prone patients. Conclusions. Compared with standard of care, PCDs have no effect on intradialytic hemodynamic parameters, including CBV, although they may allow greater capacity for fluid removal. Further studies are required to better understand physiological and hemodynamic changes in patients during HD.
I N T RO D U C T I O N
Intradialytic hypotension (IDH), the most common complication during chronic hemodialysis (HD), is associated with increased morbidity and mortality [1] . Even with current technology, IDH occurs in 20-30% of HD sessions [2] [3] [4] . Despite its prevalence, the pathophysiology of IDH is poorly understood. Studies in patients without IDH demonstrate that fluid removal during HD reduces extracellular fluid (ECF) volume while conserving central blood volume (CBV) [5, 6] , which is defined as the blood volume in the cardiopulmonary circulation plus the great vessels (0.8-1.6 L) [7] . In these stable HD patients, reduction in the ECF volume occurs preferentially in the extremities over the trunk [6, 8, 9] . Thus, CBV has a role in preserving hemodynamic stability during HD [7] , and its preservation is intimately related to fluid loss and refilling in the extremities [9] .
Pneumatic compression devices (PCDs) are a well-established preventative therapy for deep venous thrombosis [10] . When sequential compression is applied to the limbs, a pressure gradient is created, accelerating blood flow [11] , increasing leg blood volume [12] , and potentially increasing cardiac venous return [11, 13] . Thus, PCD-induced changes in venous return could potentially improve CBV and hemodynamic stability in HD patients. However, few studies have examined the potential uses of PCDs during HD. PCDs have been reported to prevent intradialytic muscle cramps [14] and optimize ultrafiltration (UF) in edematous patients [15] , but they have not been studied for IDH prevention. Furthermore, no studies have investigated the effect of PCDs on hemodynamic parameters during HD, such as blood pressure and CBV. Thus, we sought to determine the effect of PCDs compared with the standard of care on CBV during HD in a randomized controlled trial.
S U B J E C T S A N D M E T H O D S
We performed a two-period, two-treatment, randomized crossover trial. All patients provided written informed consent. The study protocol was approved by the Conjoint Health Research Ethics Board at the University of Calgary, and was conducted in accordance with the Declaration of Helsinki (ClinicalTrials.gov, NCT01067170).
Study participants
Eligible patients were recruited from two HD units in Calgary, Alberta, Canada. Eligible patients were ≥18 years, and on outpatient conventional HD three times per week for ≥3 months. Exclusion criteria included receiving HD through a central venous catheter, vascular access dysfunction (change in monthly access flow ≥25%), severe peripheral vascular disease (lower extremity arterial/venous ulcers, gangrene/necrosis, amputation, previous revascularization), active medical issues or inability to provide informed consent.
Study protocol
The study period consisted of two consecutive mid-week HD sessions. Patients were randomized to begin with either one mid-week session of HD with PCDs (intervention) or one mid-week session of standard HD (control). A single mid-week session for each strategy was chosen as the outcome measures of interest are achievable in this time frame [16, 17] .
Patients were randomized to one of two treatment sequences, stratified according to IDH-prone status. IDH was defined as a drop in systolic blood pressure (SBP) ≥20 mmHg to <100 mmHg with any intervention or patient symptoms [18] . If the pre-HD SBP was <100 mmHg, IDH was defined as a drop in SBP ≥10 mmHg with any intervention or patient symptoms. Based on previous studies, patients with IDH in ≥30% of HD sessions during the prior 4 weeks were identified as IDH-prone [16, 19, 20] . Randomization was determined by a computer-generated random number list, and concealed in opaque envelopes to ensure allocation concealment. For sequence 1, patients received one mid-week HD session with PCDs, followed by one mid-week HD session without PCDs. For sequence 2, patients received one mid-week HD session without PCDs, followed by one midweek HD session with PCDs. Given the nature of the intervention, blinding was not possible.
During the intervention session, patients received thighhigh pneumatic compressions using the Kendall 7325 Response Compression System (Covidien, Mansfield, MA), which consists of the SCD RESPONSE™ controller, non-disposable tubing and single-patient use leg garments. Sequential, circumferential, gradient compressions were applied intermittently at 45 mmHg; cycles consisted of 11 s compression, 60 s decompression.
Study patients were dialyzed using Gambro Phoenix ® dialysis systems (Gambro-Hospal, Mirandola, Italy), three times per week for 4 h each session. Each patient's target weight was optimized at the study start by the rounding nephrologist using clinical assessment. There was no change made to HD prescriptions (dialyzers, blood flow rates, dialysate flow rates, dialysate temperatures, dialysate compositions and profiles, anticoagulation), patient position, target weight or antihypertensive medication during the study period. Unless otherwise prescribed, the default dialysate sodium was 137 mmol/L, and the dialysate temperature was 36°C.
Study outcomes
The primary outcome was change in CBV during HD. Secondary outcomes were the change in other hemodynamic and fluid parameters during HD, both overall and in IDHprone patients.
Patients had each hemodynamic and fluid parameter measured twice while resting supine within the first and last 30 min of each HD session, with the mean of the two measurements used. Hemodynamic and fluid parameters were measured without interrupting the PCD compressiondecompression cycle and without stopping UF. CBV, cardiac output (CO), cardiac index (CI) and systemic vascular resistance (SVR) were determined using the ultrasound dilution technique as previously described (Transonic Inc., Ithaca, NY) [21] . Total body water (TBW), ECF volume, and intracellular fluid (ICF) volume were determined by bioimpedance spectroscopy (Quantum II, RJL Systems Inc., Clinton Township, MI) as previously described and validated [22, 23] , using the standard distal tetrapolar lead arrangement [24] on patients' non-vascular access side. Extracellular volume status was quantified using ECF:TBW and ECF:ICF ratios.
For each HD session, SBP, diastolic blood pressure, heart rate, temperature and weight were recorded both before and after the HD session ( prior to the application of PCDs for pre-HD readings, and following their removal for post-HD readings). Intradialytic blood pressure and heart rate were measured every 30 min. Blood pressures were measured using automatic blood pressure monitors (Welch Allyn Canada Ltd., Mississauga, ON). The presence of intradialytic symptoms (nausea, vomiting, light headedness, dizziness, muscle cramps, headache and diaphoresis) during the HD sessions was recorded for the purposes of defining IDH [18] .
Patient demographics, comorbidities, medications and HD prescriptions were abstracted from HD charts and the Southern Alberta Renal Program database [25] .
Statistical analysis
Sample size calculations were based on the studies demonstrating intradialytic CBV decrease by 0.13 L in stable patients [17] and 0.16 L in patients with IDH [16] . Although no prior studies exist for comparison, we assumed that PCDs would increase CBV by 0.2 L during HD. Based on our previous unpublished data, the estimated standard deviation of baseline CBV was 0.30. Assuming a correlation coefficient of 0.70 between repeated measurements, we estimated the standard deviation of the period differences pooled from both sequences as 0.23 for sample size determination. Using a 2 × 2 crossover design, we estimated that 44 patients would be required to demonstrate a significant increase in CBV during HD with PCDs by 0.2 L (α = 0.05, 80% power). We expected a 15% dropout rate, and thus, planned to recruit 51 patients in total.
Baseline characteristics are presented as medians and interquartile range (IQR) for continuous variables, and absolute and relative proportions for categorical variables. Unpaired comparisons were performed using the Mann-Whitney test and Fisher's exact test. Paired comparisons were performed using the Wilcoxon signed-rank test and McNemar's test. These analyses were performed using Stata 11.0 (StataCorp LP, College Station, TX).
To determine the association between treatment regimens and change in CBV, linear regression was performed (R version 2.13.0, R Foundation for Statistical Computing, Vienna, Austria) to assess if period and sequence effects were significant. In our linear model, neither period nor sequence was significant; thus, consideration of these potential effects were not necessary in our analyses. As a sensitivity analysis, a period-adjusted t-test was performed, confirming that period effects were not statistically significant. A significance level of 0.05 was used in all statistical tests.
R E S U LT S

Study participants
Patients were recruited between November 2008 and February 2011. Seventy-nine patients were screened, of which 66 were eligible (Figure 1) . Fifty-one patients were enrolled and randomly assigned to Sequence 1 (26 patients, including 6 IDH-prone) or Sequence 2 (25 patients, including 5 IDHprone) (Figure 1 ). After randomization, five patients were excluded prior to receiving the intervention: three patients (one IDH-prone) randomized to Sequence 1 were excluded due to vascular access dysfunction; one patient randomized to Sequence 2 electively withdrew from the study and another randomized to Sequence 2 (IDH-prone) died. Therefore, 46 patients (23 in each of Sequences 1 and 2) were included in our analysis (Figure 1 ).
Baseline characteristics of the 51 randomized patients are presented in Table 1 . The median age was 65 years (IQR 23 years), 75% were male, the median HD vintage was 36 months (IQR 46 months), and 74% were Caucasian (Table 1 ). There were no differences in baseline characteristics between IDH-prone and non-IDH prone patients (Table 1) .
Outcomes
During HD, the median change in CBV in the control and intervention sessions was −0.050 L versus −0.080 L, P = 0.62 (Table 2 ). There were no differences in the median change in CO, CI and SVR during HD between the control and intervention sessions (Table 2 (Table 3) . When the hydration status was expressed as ECF:TBW and ECF:ICF ratios, there was no difference in extracellular volume status at the end of HD with PCDs versus control (Table 3 ). In our sub-analysis of IDH-prone patients, similar hemodynamic and fluid results were observed (Table 4) . 
D I S C U S S I O N
To our knowledge, this is the first randomized controlled trial examining the effect of PCDs on hemodynamic and fluid parameters during HD in end-stage renal disease (ESRD) patients. We found no effect of PCDs on the primary outcome of change in CBV during HD compared with standard of care. PCDs also had no effect on CO, SVR and post-HD and intradialytic blood pressures. There was, however, a trend towards a greater reduction in TBW during HD with PCD use. Furthermore, there was a significant decrease in the ICF volume during HD with PCDs, coinciding with relative preservation of the ECF volume, suggesting that PCDs increase mobilization of fluid from the ICF, promoting ECF refill, and potentially allowing for greater fluid removal during HD.
In our sub-analysis of IDH-prone patients (n = 9), PCDs resulted in a smaller, non-significant decrease in CBV during HD. As observed overall, use of PCDs did not impact change in either CO or SVR during HD in the IDH-prone patients. Finally, similar to our overall study population, in the IDHprone patients, there was a trend towards a greater decrease in TBW during HD with PCDs, and preservation of the ECF with unchanged ECF:TBW and ECF:ICF ratios.
Few studies examine the effect of interventions on CBV during HD. In one study, both cool dialysate and midodrine significantly improved CBV preservation during HD compared with control [16] . In another study, anti-embolism stockings did not change CBV, CO or SVR in HD patients, although this study was small (n = 11) and observational in nature [26] .
Studies in healthy volunteers suggest that PCDs influence hemodynamic parameters, although results are conflicting. In one study of 20 healthy, normotensive young men, PCDs significantly increased CO due to augmented venous return and increased stroke volume (without a rise in heart rate), with a reduction in SVR [27] . In contrast, another small study of 11 healthy men and women found that PCDs significantly decreased CI and heart rate, without an increase in stroke volume, and with a significant increase in SVR [28] .
The application of PCDs for hemodynamic benefit has been studied in other settings, including cardiac and surgical patients. Among cardiac patients, PCDs have been reported to augment venous return [29] . Use of PCDs during laparoscopic surgery has been shown to reverse the adverse hemodynamic effects of pneumoperitoneum (decreased CO and stroke volume) by significantly increasing CO, stroke volume [30, 31] and blood pressure [30] , and decreasing SVR [31] .
Use of intermittent PCDs has been examined in markedly edematous chronic HD patients [15] . A small observational study (n = 11) published in 1974 found significantly greater volume removal with PCDs than standard of care [15] . However, the authors attributed this difference to reduced UF rates and additional volume infusions (to counteract hypotension) during the control HD sessions [15] . Both groups experienced IDH requiring volume infusion, but with PCDs, IDH occurred later in the HD sessions. Methods of this study are poorly reported, implying lack of standardization between control and PCD HD sessions [15] .
Why was there no intradialytic hemodynamic effect of PCDs in our study? It is possible that increased blood velocity and venous return induced by PCDs are dissipated as blood 
O R I G I N A L A R T I C L E S
P n e u m a t i c c o m p r e s s i o n d e v i c e s d u r i n g d i a l y s i s flows proximally ( perhaps exacerbated by concurrent fluid removal), therefore failing to impact CBV and other hemodynamic parameters. However, PCDs did result in a trend towards increased fluid removal during HD, as measured by changes in TBW, ECF volume and ICF volume, suggesting that PCDs may improve capacity for UF. It is also possible that PCDs have a negligible hemodynamic effect during HD in stable patients who are not significantly volume expanded, perhaps reflecting the healthy volunteer bias observed in some studies [32] . Our study population consisted of mostly stable euvolemic patients who were not prone to IDH and who were not as volume overloaded as expected, as evidenced by our pre-HD ECF:TBW and ECF:ICF ratios of approximately 44% and 0.80, respectively. These ratios are essentially normal when compared with results from: (1) the healthy control groups from other dialysis studies [5, 6, 33] and (2) the accepted normal range for ECF:TBW reported in the literature [33, 34] . Unlike other studies of HD patients in which volume removal occurs from the ECF only [6, 8, 9, 17] , in our study, volume reduction during HD occurred from both the ECF and ICF, further supporting the notion that our patients were not greatly volume expanded. Intuitively, volume removal would occur from the ECF alone in volume-expanded patients, but from both the ECF and ICF in euvolemic patients due to intravascular refilling. In contrast to our results, other studies of fluid compartments in HD patients have consistently revealed expanded extracellular volume, even after UF [5, 6, 35] . The difference in volume status between our HD patients and HD patients in other studies likely reflects the differences in practice patterns, as we use a low sodium dialysate of 137 mmol/L, rather than 140 mmol/ L as reported in other studies [6, 9] .
Our study was conceived with the notion that PCDs would maintain CBV during HD, and thus promote intradialytic hemodynamic stability. Given that our study Black n (%) 1 (2) 1 (2.5) 0 (0)
Asian n (%) 10 (20) 7 (17.5) 3 (27) Aboriginal n (%) 2 (4) 0 (0) 2 (18) Reason for ESRD 0.87
HTN n (%) 14 (27) 10 (25) 4 (36) GN n (%) 9 (18) 8 (20) 1 (9) Cystic n (%)
Other n (%) 3 (6) 2 (5) 1 (9) Comorbid conditions DM n (%) 25 (49) 18 (45) included only nine IDH-prone patients, and that of these, only four had IDH during the study (two during the control session and two during the intervention session), we are unable to determine the effect of PCDs in IDH-prone patients. More studies are required to determine whether PCDs have greater hemodynamic impact and whether they allow for more tolerable fluid removal in this unstable patient population.
Our study results should be interpreted within the context of limitations. We did not quantify or standardize the effectiveness of our intervention, PCDs, by measuring the actual venous flow velocity. It is possible that there was insufficient pressure to impact venous flow and central hemodynamics with PCDs during HD. Because this was a proof of principle study, we did not investigate different types of compression systems; the degree of venous flow augmentation with PCDs depends on several factors (the compression-decompression duration ratio, the rate of insufflation, the number of cells in PCDs, the distribution of pressure over the lower limbs, the maximum pressure reached in each cell and the arrangement of the cells) [30] . However, PCDs were applied as tightly as possible, allowing for patient comfort, an important endpoint in itself as it speaks to patients' potential acceptance of the intervention. PCDs were not turned off during hemodynamic and fluid measurements, which may have affected the results. Despite continuing compression cycles during measurements, our results still showed no difference between intervention and control sessions, further supporting the lack of hemodynamic effect with PCDs during HD. Whole body bioimpedance was used to measure fluid compartments rather than segmental bioimpedance which may have revealed more information about how fluid is removed from different body compartments with PCDs, although this would not have impacted evaluation of our primary outcome. Bioimpedance measurements were performed during HD without discontinuing UF, and without removing jewelry/metal from study participants, which may have influenced fluid compartment results. However, actual UF volumes were similar to measured TBW reductions (Table 3) . Because bioimpedance measurements and HD were performed similarly for control and intervention sessions, and because patients acted as their own controls, any inaccuracies in fluid measurements would have had consistent impact on both study sessions. Besides, bioimpedance measurements have been previously studied during UF and HD. With UF, intracellular and extracellular resistivities for bioimpedance fluid compartment estimations should not be greatly affected [22] ; transcellular water shifts should not change the intracellular and extracellular conductivities because ions move freely with fluid [22] . Our study included only a small proportion of IDH-prone patients, and was not powered to detect a difference in this sub-group. We excluded patients dialyzing with central venous catheters from our study, patients who tend to have greater comorbidity [36] . In doing so, we eliminated a large body of patients who may have potentially benefitted from PCDs, again contributing to healthy volunteer bias. Finally, although the pre-HD baseline values of CO, CI and SVR for the control and intervention sessions were significantly different, the clinical relevance of these differences is questionable, and likely reflects the underlying vascular variability of the ESRD population. Furthermore, there was no statistical difference in intradialytic change in these hemodynamic parameters when control and intervention sessions were compared. Despite limitations, our study has many strengths. It is unique, well designed and large compared with other physiological studies in HD patients [5, 6, 8, 9, 16, 17, 37, 38] , and contributes to the current evidence in nephrology which is lacking in randomized controlled trials [12, 39] . Our study adds to the body of literature on the subject of hemodynamic changes during HD, as well as the use of ultrasound dilution and bioimpedance spectroscopy in HD patients.
In summary, this is the first randomized controlled trial in HD patients investigating the effect of PCDs on intradialytic hemodynamic parameters. Compared with the standard of care, PCDs had no effect on CBV, CO and SVR in HD patients. However, PCDs may improve tolerability for greater volume removal during HD by shifting fluid from intracellular compartments. This trend is worthy of further investigation, and should be explored in a large prospective study of volume overloaded IDH-prone patients. 
CO N F L I C T O F I N T E R E S T S TAT E M E N T
See related article by Raimann and Levin. Pneumatic compression devices to avoid intradialytic morbid events. Nephrol Dial Transplant 2013; 28: 779-781.)
